SCHEMBL2396572

SCHEMBL2396572

c1ccc2[nH]c(-c3ncc4[nH]cnc4n3)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 1/20 0.44
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
CYP19A1 P11511 1/20 0.43
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 4/20 0.42
GSK3B P49841 1/20 0.41
ITK Q08881 2/20 0.40
MAPT P10636 4/20 0.40
MEN1 O00255 3/20 0.40
HPGD P15428 3/20 0.40
KMT2A Q03164 3/20 0.40
CASP3 P42574 2/20 0.40
SENP8 Q96LD8 2/20 0.40
SENP7 Q9BQF6 2/20 0.40
SENP6 Q9GZR1 2/20 0.40
CHEK1 O14757 1/20 0.40
KDR P35968 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4043730 0.75 RAB9A (0.49) RAB9ANPC1CYP19A1KDM4EALDH1A1
SCHEMBL29452971 0.75 ALDH1A1 (0.63) CDK2KDM4EALDH1A1HPGDCHEK1
SCHEMBL680856 0.74 CDK2 (0.55) CDK2RAB9ANPC1KDM4EALDH1A1
SCHEMBL369487 0.73 NPC1 (0.51) CDK2RAB9ANPC1KDM4EALDH1A1
SCHEMBL1563154 0.73 RAB9A (0.50) RAB9ANPC1CYP19A1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL4456682 0.73 CDK2 (0.54) CDK2RAB9ANPC1KDM4EALDH1A1
SCHEMBL2489128 0.72 ITK (0.57) RAB9ANPC1CYP19A1KDM4EALDH1A1
SCHEMBL30337474 0.72 ITK (0.57) RAB9ANPC1CYP19A1KDM4EALDH1A1
SCHEMBL28399450 0.71 RAB9A (0.61) RAB9ANPC1CYP19A1KDM4EALDH1A1
SCHEMBL4924100 0.71 KDM4E (0.48) CDK2RAB9ANPC1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2215090-B1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-03-04 EP disclosed
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-22 US disclosed
EP-2215090-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-08-11 EP disclosed
WO-2009053716-A1 PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230464-A1 PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS PIK3CA, PIK3CD, PI4KA CDK2 129/4885RAB9A 1821/4885NPC1 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.